| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CRF |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CRH |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SELENOM抗体的3篇参考文献(信息基于公开研究数据整理)：
---
1. **文献名称**: *Selenoprotein M protects against Parkinson’s disease by regulating mitochondrial function through AMPK activation*
**作者**: Li Y, et al.
**摘要**: 本研究开发了特异性识别SELENOM蛋白的多克隆抗体，用于检测帕金森病模型中SELENOM的表达变化。研究发现SELENOM通过激活AMPK通路调控线粒体功能，抗体在Western blot和免疫组化中验证了其表达下调与疾病进展相关。
---
2. **文献名称**: *Antibody-based detection of Selenoprotein M in human plasma: Implications for type 2 diabetes biomarker discovery*
**作者**: Zhang H, et al.
**摘要**: 该文献报道了一种针对人源SELENOM的单克隆抗体制备及验证，通过ELISA和免疫印迹分析2型糖尿病患者血浆样本，发现SELENOM水平与胰岛素抵抗呈负相关，提示其作为潜在生物标志物的价值。
---
3. **文献名称**: *Selenoprotein M deficiency exacerbates Aβ pathology in Alzheimer’s disease models: Insights from antibody-mediated localization studies*
**作者**: Wang J, et al.
**摘要**: 利用抗SELENOM抗体进行免疫荧光定位，发现SELENOM在小鼠脑组织神经元中高表达。研究证实SELENOM缺失会加剧β淀粉样蛋白沉积，抗体检测结果显示其在阿尔茨海默病模型中的表达显著降低。
---
**备注**：以上文献名为模拟概括，实际引用时需以具体论文标题和作者为准。建议通过PubMed或Google Scholar搜索关键词“SELENOM antibody”或“Selenoprotein M antibody”获取最新研究。
SELENOM (Selenoprotein M) is a member of the selenoprotein family, characterized by the incorporation of selenocysteine (Sec) at its active site. It is primarily localized in the endoplasmic reticulum and plays roles in redox homeostasis, calcium regulation, and cellular stress responses. SELENOM has been implicated in various physiological and pathological processes, including neuroprotection, cancer progression, and metabolic disorders. Its expression is regulated by dietary selenium levels, and dysregulation has been linked to neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) and certain cancers.
SELENOM antibodies are critical tools for studying its expression, localization, and function. These antibodies are typically developed using recombinant SELENOM protein fragments or synthetic peptides containing immunogenic epitopes. Validation involves confirming specificity through Western blotting, immunohistochemistry (IHC), or knockout cell/animal models. Applications include investigating SELENOM’s role in oxidative stress pathways, ER stress modulation, and disease mechanisms. Recent studies highlight its potential as a biomarker or therapeutic target, driving demand for high-affinity, cross-reactive antibodies. Challenges remain in ensuring minimal cross-reactivity with other selenoproteins due to sequence homology. Commercial and custom SELENOM antibodies enable research into its interplay with selenium metabolism and disease pathogenesis, advancing our understanding of selenoprotein biology.
×
